Findings

What do systematic reviews say?

Refine by population, intervention, comparison or outcome
More filters
Evidence found and GRADE certainty

141 questions · 153 findings · 16 reviews · Urology

No studies found 42 · 27.5%GRADE not reported 2 · 1.3%Very low 16 · 10.5%Low 56 · 36.6%Moderate 33 · 21.6%High 4 · 2.6%

Intervention not reported

Overall survival (OS) ‐ Network (subnet 1) included 19 pairwise comparisons ‐ Median · people with a confirmed diagnosis of advanced renal cell carcinoma (combined risk groups) without previous systemic anticancer therapy

The intervention showed no clear difference in overall survival (OS) ‐ Network (subnet 1) included 19 pairwise… (moderate certainty).

1 finding from 1 review

Intervention not reported

Serious adverse events (SAEs) ‐ Network included 31 pairwise comparisons ‐ Mean risk with SUN across trials3 included in this network: 40.7% · people with a confirmed diagnosis of advanced renal cell carcinoma (combined risk groups) without previous systemic anticancer therapy

The intervention showed no clear difference in serious adverse events (SAEs) ‐ Network included 31 pairwise… (moderate certainty).

1 finding from 1 review

Intervention not reported

Progression‐free survival (PFS) ‐ Network (subnet 1) included 27 pairwise comparisons ‐ Median · people with a confirmed diagnosis of advanced renal cell carcinoma (combined risk groups) without previous systemic anticancer therapy

The intervention probably leads to lower progression‐free survival (PFS) ‐ Network (subnet 1) included 27… (moderate certainty).

1 finding from 1 review

Intervention not reported

Adverse events (AEs) (grade 3 or 4) ‐ Network included 19 pairwise comparisons ‐ Mean risk with SUN across trials3 in this network: 70.6% · people with a confirmed diagnosis of advanced renal cell carcinoma (combined risk groups) without previous systemic anticancer therapy
1 finding from 1 review

Intervention not reported

Time to initiation of first subsequent therapy This outcome was not reported as a time‐to‐event outcome. Instead, authors of the trials reported the number of participants who received subsequent anticancer therapy after discontinuation of trial t... · people with a confirmed diagnosis of advanced renal cell carcinoma (combined risk groups) without previous systemic anticancer therapy

The intervention may leads to lower time to initiation of first subsequent therapy This outcome was not… (low certainty).

1 finding from 1 review